Skip to main content

Incyte ICLUSIG revenue

  • INCY · Nasdaq
  • Biotechnology
  • S&P 500
$120.97−0.60%Close 13 Nov 2026 · Market value $24.66B

ICLUSIG revenue at Incyte came to $33.5M for the quarter to 30 Sep 2026, down 10.8% from a year earlier.

As Incyte reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$27.1MDec 2023$30.3MMar 2024$26.9MJun 2024$29.7MSep 2024$27.4MDec 2024$29.5MMar 2025$32.7MJun 2025$37.6MSep 2025$34.2MDec 2025$35.5MMar 2026$34.4MJun 2026$33.5MSep 2026
Incyte ICLUSIG revenue, every reported period
Period endingICLUSIG revenueChange on a yearFiled
30 Sep 2026$33.5Mdown 10.8%29 Oct 2026
30 Jun 2026$34.4Mup 5.1%28 Jul 2026
31 Mar 2026$35.5Mup 20.0%28 Apr 2026
31 Dec 2025$34.2Mup 25.0%10 Feb 2026
30 Sep 2025$37.6Mup 26.3%28 Oct 2025
30 Jun 2025$32.7Mup 21.8%29 Jul 2025
31 Mar 2025$29.5Mdown 2.6%29 Apr 2025
31 Dec 2024$27.4Mup 0.9%10 Feb 2025
30 Sep 2024$29.7Mup 7.3%29 Oct 2024
30 Jun 2024$26.9Mdown 7.6%30 Jul 2024
31 Mar 2024$30.3Mup 9.6%30 Apr 2024
31 Dec 2023$27.1Mdown 1.8%13 Feb 2024
30 Sep 2023$27.7Mup 6.9%31 Oct 2023
30 Jun 2023$29.1Mup 10.9%1 Aug 2023
31 Mar 2023$27.7Mup 6.2%2 May 2023
31 Dec 2022$27.6M—7 Feb 2023
30 Sep 2022$25.9M—1 Nov 2022
30 Jun 2022$26.2M—2 Aug 2022
31 Mar 2022$26.1M—3 May 2022

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Incyte: Customer A (change on a year) · Customer B (change on a year) · Customer C (change on a year) · JAKAFI revenue · OPZELURA revenue · Product royalty revenues · JAKAVI revenue · NIKTIMVO revenue · ZYNYZ revenue · MINJUVI/MONJUVI revenue · Milestone and contract revenues · OLUMIANT revenue · PEMAZYRE revenue · TABRECTA revenue · United States revenue · Europe revenue · financial statements

Every KPI and segment of INCY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.